AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24118369 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading an online news article about a genetic basis for nicotine addiction and lung cancer
Number of subjects: 333
Study 24118369 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading an online news article indicating no genetic basis for nicotine addiction and lung cancer
Number of subjects: 333
Study 24118369 — intervention group
Group type: COMPARATOR
Intervention: Reading an unrelated attention control article
Number of subjects: 333
Study 23027229 — intervention group
Group type: EXPERIMENTAL
Intervention: Depleted self-control strength
Number of subjects: 143
Study 23027229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully available self-control strength
Number of subjects: 143
Study 23027229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low state anxiety
Number of subjects: 143
Study 23027229 — intervention group
Group type: EXPERIMENTAL
Intervention: High state anxiety
Number of subjects: 143
Study 20601853 — intervention group
Group type: EXPERIMENTAL
Intervention: Online, interactive sexual risk reduction intervention
Number of subjects: 650
Study 20601853 — intervention group
Group type: COMPARATOR
Intervention: Waitlist null control
Number of subjects: 650
Study 17663731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 U s.c. daily until 20 weeks and then 5,000 U s.c. q12 h until >37 weeks
Number of subjects: 62
Study 17663731 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a mean of 38 days of postpartum dalteparin
Number of subjects: 62
Study 15643099 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oxazepam
Number of subjects: 34
Study 15643099 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oxazepam
Number of subjects: 34
Study 15643099 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oxazepam
Number of subjects: 34
Study 15643099 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg and 30 mg oxazepam
Number of subjects: 34
Study 12200754 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion at rates of 0.2, 0.5, 2, 6, and 8 ng.kg(‐1).min(‐1)
Number of subjects: 17
Study 12200754 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion at rates of 6 and 8 ng.kg(‐1).min(‐1)
Number of subjects: 17
Study 12200754 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion (all rates)
Number of subjects: 17
Study 10206284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour S-phase fraction over 17%
Number of subjects: 217
Study 10206284 — intervention group
Group type: COMPARATOR
Intervention: Tumour S-phase fraction lower than 8%
Number of subjects: 217
Study 10206284 — intervention group
Group type: COMPARATOR
Intervention: Tumour S-phase fraction between 8-17%
Number of subjects: 217
Study 7762725 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health nursing intervention consisting of telephone contacts or home visits
Number of subjects: 1654
Study 7762725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1654
Study 2181991 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human leucocyte interferon-alpha A (2.5, 5.0 or 10.0 million units/m2)
Number of subjects: 30
Study 2181991 — intervention group
Group type: COMPARATOR
Intervention: Control (observation for 18 months without active treatment)
Number of subjects: 30
Study 436305 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride infusion (intravenous)
Number of subjects: 11
Study 436305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulpiride treatment for 5 days
Number of subjects: 11
Study 436305 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study 31793084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraslow full-power shock wave lithotripsy (group A)
Number of subjects: 196
Study 31793084 — intervention group
Group type: COMPARATOR
Intervention: Slow power-ramping shock wave lithotripsy (group B)
Number of subjects: 196
Study 31793084 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 196
Study 31200756 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS, 7.3% NaCl) infused at 5 ml/kg ideal body weight
Number of subjects: 96
Study 31200756 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS, 0.9% NaCl)
Number of subjects: 96
Study 31200756 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS)
Number of subjects: 96
Study 31200756 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 96
Study 27570246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal Biacuplasty + Conservative Medical Management (IDB+CMM)
Number of subjects: 63
Study 27570246 — intervention group
Group type: COMPARATOR
Intervention: CMM-alone
Number of subjects: 63
Study 25840597 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Number of subjects: 598
Study 25840597 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bortezomib
Number of subjects: 598
Study 23990499 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy administered intravenously for 6 weeks
Number of subjects: 12
Study 23990499 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy
Number of subjects: 12
Study 23990499 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 12
Study 21183418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20‐60 mg/day), hypolipidemic diet and physical training
Number of subjects: 83
Study 21183418 — intervention group
Group type: COMPARATOR
Intervention: Hypolipidemic diet and physical training
Number of subjects: 83
Study 19331435 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 325 mg
Number of subjects: 277
Study 16710614 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC (up to 6 units) in the first 12 hours
Number of subjects: 720
Study 16710614 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid followed by stored RBCs
Number of subjects: 720
Study 15260910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (maximum dose 20 mg b.i.d.)
Number of subjects: 15
Study 15260910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11417267 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB-ethanolamide (150 mg/kg i.v. followed by 150 mg/kg/h)
Number of subjects: 29
Study 11417267 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.025 mg/kg i.v. followed by 0.025 mg/kg/h)
Number of subjects: 29
Study 9023465 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 or 50 mg)
Number of subjects: 313
Study 9023465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 8420065 — intervention group
Group type: EXPERIMENTAL
Intervention: rh-SOD
Number of subjects: 116
Study 8420065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 2950910 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane via mask (spontaneous respiration)
Number of subjects: 60
Study 2950910 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane via tracheal tube (spontaneous respiration)
Number of subjects: 60
Study 2950910 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane via tracheal tube with controlled ventilation
Number of subjects: 60
Study 29314208 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased lesional volume (per 10ml)
Number of subjects: 298
Study 29314208 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 298
Study 27678439 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcabene 300 mg
Number of subjects: 66
Study 27678439 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcabene 900 mg
Number of subjects: 66
Study 27678439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 25620399 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE
Number of subjects: 7
Study 25620399 — intervention group
Group type: EXPERIMENTAL
Intervention: PC+ICE
Number of subjects: 7
Study 24036846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg p.o.
Number of subjects: 11
Study 24036846 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate 4,000 mg (4 X Tums Ultra 1000®) p.o. 15 min prior to nilotinib dose.
Number of subjects: 11
Study 20837914 — intervention group
Group type: COMPARATOR
Intervention: PVR alone
Number of subjects: 64
Study 20837914 — intervention group
Group type: EXPERIMENTAL
Intervention: PVR with surgical RV remodeling
Number of subjects: 64
Study 18380739 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery (ECH)
Number of subjects: 60
Study 18380739 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 60
Study 18380739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashears (USH)
Number of subjects: 60
Study 16227665 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11961344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (100 microg/h, infused intravenously over 7 h)
Number of subjects: 20
Study 11961344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11961344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 20
Study 10078400 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lidocaine 2% (L2%) with epinephrine
Number of subjects: 90
Study 10078400 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg bupivacaine 0.25% (B0.25%)
Number of subjects: 90
Study 10078400 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg bupivacaine 0.5% (B0.5%)
Number of subjects: 90
Study 7675271 — intervention group
Group type: COMPARATOR
Intervention: HBO
Number of subjects: 17
Study 7675271 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO + NAC (1800 mg/day)
Number of subjects: 17
Study 2149501 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide low dose (125 mg bid)
Number of subjects: 0
Study 2149501 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide medium dose (250 mg bid)
Number of subjects: 0
Study 2149501 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide low dose (125 mg bid) + Hydrocortisone (20 mg bid)
Number of subjects: 0
Study 2149501 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide medium dose (250 mg bid) + Hydrocortisone (20 mg bid)
Number of subjects: 0
Study 2149501 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone alone (20 mg bid)
Number of subjects: 0
Study 7020916 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC (dimethyl triazeno imidazole carboxamide), 4 courses in 12 months, at 4.5 mg/kg/d x 10
Number of subjects: 174
Study 7020916 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 174
Study 7020916 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC therapy in patients who developed thrombocytopenia
Number of subjects: 174
Study 30908365 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 2 times per week (G2x, 3 sets)
Number of subjects: 47
Study 30908365 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 3 times per week (G3x, 2 sets)
Number of subjects: 47
Study 30882596 — intervention group
Group type: EXPERIMENTAL
Intervention: Not taking antihypertensive medications
Number of subjects: 692
Study 30882596 — intervention group
Group type: COMPARATOR
Intervention: Taking antihypertensive medications
Number of subjects: 692
Study 29941057 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (AL) 882 mg
Number of subjects: 190
Study 27071730 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 1236
Study 27071730 — intervention group
Group type: COMPARATOR
Intervention: Control (no snus)
Number of subjects: 1236
Study 25391887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted transoral approach (EATA)
Number of subjects: 20
Study 25391887 — intervention group
Group type: COMPARATOR
Intervention: External approaches (EA)
Number of subjects: 20
Study 23298824 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement (5000 IU/day)
Number of subjects: 100
Study 23298824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20734049 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple regimen (oral aprepitant 125 mg, intravenous ondansetron 32 mg, oral dexamethasone 12 mg on day 1; aprepitant 80 mg and dexamethasone 8 mg days 2-3; dexamethasone 8 mg day 4)
Number of subjects: 12
Study 20734049 — intervention group
Group type: COMPARATOR
Intervention: Dual regimen (intravenous ondansetron 32 mg and dexamethasone 20 mg on day 1; dexamethasone 8 mg bid days 2-4)
Number of subjects: 12
Study 20734049 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both regimens
Number of subjects: 12
Study 18650174 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line erlotinib followed by second-line cisplatin/gemcitabine
Number of subjects: 900
Study 18650174 — intervention group
Group type: COMPARATOR
Intervention: First-line cisplatin/gemcitabine followed by second-line erlotinib
Number of subjects: 900
Study 18650174 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line erlotinib
Number of subjects: 900
Study 18650174 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line erlotinib followed by chemotherapy
Number of subjects: 900
Study 17142138 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/d)
Number of subjects: 33
Study 17142138 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/d)
Number of subjects: 33
Study 12617525 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-LODEC software for decomposition of multichannel long-term EMG signals
Number of subjects: 0
Study 12617525 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet-based hierarchical cluster analysis algorithm
Number of subjects: 0
Study 12617525 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted averaging method using three channels
Number of subjects: 0
Study 12617525 — intervention group
Group type: EXPERIMENTAL
Intervention: Decomposition of nonclassified segments using class-mean signals
Number of subjects: 0
Study 11729370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas (n=121)
Number of subjects: 245
Study 11729370 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medications other than sulfonylureas (n=17)
Number of subjects: 245
Study 11729370 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (n=28)
Number of subjects: 245
Study 11729370 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (n=79)
Number of subjects: 245
Study 9256570 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group (computer‐based behavioral self‐control training)
Number of subjects: 40
Study 9256570 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group (computer‐based behavioral self‐control training after a 10-week waiting period)
Number of subjects: 40
Study 8287662 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (n = 48)
Number of subjects: 72
Study 8287662 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 72
Study 3603369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal position for irradiation
Number of subjects: 12
Study 3603369 — intervention group
Group type: COMPARATOR
Intervention: Semi-lateral position for irradiation
Number of subjects: 12
Study 30747566 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-stride approach
Number of subjects: 12
Study 30747566 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-stride approach
Number of subjects: 12
Study 30747566 — intervention group
Group type: EXPERIMENTAL
Intervention: Global positioning satellite location (L4)
Number of subjects: 12
Study 30747566 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery length
Number of subjects: 12
Study 30236998 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational support (ARM1)
Number of subjects: 11609
Study 30236998 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender rights awareness (ARM2)
Number of subjects: 11609
Study 30236998 — intervention group
Group type: EXPERIMENTAL
Intervention: Livelihoods training (ARM3)
Number of subjects: 11609
Study 30236998 — intervention group
Group type: COMPARATOR
Intervention: Control area (ARM4)
Number of subjects: 11609
Study 25488849 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized respiratory muscle training device combined with conventional physical therapy
Number of subjects: 20
Study 25488849 — intervention group
Group type: COMPARATOR
Intervention: Basic exercise treatments for 30 min followed by an automated full‐body workout for 20 min
Number of subjects: 20
Study 23107387 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention promoting protective infant feeding practices; Duration: Not specified.
Number of subjects: 86
Study 23107387 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; Control group not specified.
Number of subjects: 86
Study 20454891 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose B-complex vitamin and mineral supplement (Berocca(R))
Number of subjects: 215
Study 18590758 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based multi-factorial lifestyle intervention
Number of subjects: 6091
Study 18590758 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 6091
Study 16368826 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 50 mg/d PO
Number of subjects: 100
Study 16368826 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 1.2 g/d PO
Number of subjects: 100
Study 16368826 — intervention group
Group type: COMPARATOR
Intervention: Combination of rofecoxib 50 mg/d and gabapentin 1.2 g/d PO
Number of subjects: 100
Study 14569096 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (fosinopril; 20 mg/d)
Number of subjects: 10
Study 14569096 — intervention group
Group type: COMPARATOR
Intervention: ARB (irbesartan; 150 mg/d)
Number of subjects: 10
Study 14569096 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 10
Study 10777036 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (1 mg three times daily)
Number of subjects: 10
Study 10777036 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (1 mL/kg)
Number of subjects: 10
Study 10777036 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin with alcohol ingestion
Number of subjects: 10
Study 10777036 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control drink
Number of subjects: 10
Study 8876513 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein‐energy supplement
Number of subjects: 0
Study 8876513 — intervention group
Group type: COMPARATOR
Intervention: Low protein‐energy supplement (nonsupplemented children)
Number of subjects: 0
Study 2142323 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary inpatient treatment for 4-6 weeks
Number of subjects: 100
Study 2142323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study 74141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chemotherapy with low doses of Vinblastine and subsequent chemotherapy based on 99m‐Tc ‐‐labelled Bleomycin uptake
Number of subjects: 61
Study 74141 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy based on individual Tc‐Bleomycin uptake curves
Number of subjects: 61
Study 74141 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in 23 patients with previously untreated T3 tumors
Number of subjects: 61
Study 74141 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy overall
Number of subjects: 61
Study 30496532 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacity enhancement intervention
Number of subjects: 65
Study 30496532 — intervention group
Group type: COMPARATOR
Intervention: Standard dissemination
Number of subjects: 65
Study 31070471 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity rosuvastatin
Number of subjects: 11269
Study 31070471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11269
Study 28434097 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary/integrative medicine (CIM) treatments
Number of subjects: 205
Study 28434097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IP consultation)
Number of subjects: 205
Study 25984802 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular EBT
Number of subjects: 145
Study 25984802 — intervention group
Group type: COMPARATOR
Intervention: Standard EBT
Number of subjects: 145
Study 25984802 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 145
Study 23958407 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2.0 g as calcium carbonate)
Number of subjects: 92
Study 23958407 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D3 (800 IU)
Number of subjects: 92
Study 23958407 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2.0 g as calcium carbonate) and Calcium plus vitamin D3 (800 IU) pooled
Number of subjects: 92
Study 21752880 — intervention group
Group type: EXPERIMENTAL
Intervention: MBX-8025 (50 or 100 mg)
Number of subjects: 181
Study 21752880 — intervention group
Group type: EXPERIMENTAL
Intervention: MBX-8025 (50 or 100 mg) combined with atorvastatin (20 mg)
Number of subjects: 181
Study 21752880 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (20 mg)
Number of subjects: 181
Study 21752880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 19635616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/conjugated estrogens (BZA/CE)
Number of subjects: 3397
Study 19635616 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (60 mg)
Number of subjects: 3397
Study 19635616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study 22707560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (9 g/day; 1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)
Number of subjects: 67
Study 22707560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil; 9 g/day)
Number of subjects: 67
Study 15696983 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA + IPL
Number of subjects: 10